C16-PAF

C16-PAF (PAF (C16) ), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR) . C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability[1][2][3][4][5].

Product Specifications

CAS Number

[74389-68-7]

Product Name Alternative

PAF (C16)

UNSPSC

12352211

Target

Endogenous Metabolite; ERK; MEK; p38 MAPK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; Metabolic Enzyme/Protease; Stem Cell/Wnt

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/c16-paf.html

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP(OCC[N+](C)(C)C)([O-])=O

Molecular Formula

C26H54NO7P

Molecular Weight

523.68

References & Citations

[1]Scott D Ryan, et al. Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons. J Lipid Res. 2008 Oct;49 (10) :2250-8.|[2]Z Honda, et al. Transfected platelet-activating factor receptor activates mitogen-activated protein (MAP) kinase and MAP kinase kinase in Chinese hamster ovary cells. J Biol Chem. 1994 Jan 21;269 (3) :2307-15.|[3]Muhammad S Riaz, et al. Direct Growth Inhibitory Effect of Platelet Activating Factor C-16 and Its Structural Analogs on Mycobacteria. Front Microbiol. 2018 Sep 11;9:1903.|[4]Jing Chu, et al. IGHG1 Regulates Prostate Cancer Growth via the MEK/ERK/c-Myc Pathway. Biomed Res Int. 2019 Jul 4;2019:7201562.|[5]Nina Bögershausen, et al. RAP1-mediated MEK/ERK pathway defects in Kabuki syndrome. J Clin Invest. 2015 Sep;125 (9) :3585-99.